BMS puts a $250-million chip on expanded biotech capabilities in Devens, MA
Expansion will enable more process development and clinical-trials manufacturing, add 350 employees
The Devens, MA facility of Bristol-Myers Squibb was a $750-million trophy win for the state of Massachusetts back in 2009, when the state provided resources to convert an old military base to commercial use. Now, an additional $250 million is being committed to the site, adding 200,000 sq. ft of constructed space to the existing 400,000 sq. ft. BMS says that two new buildings will be constructed, one for developing manufacturing processes for investigational biologics, and another for clinical-scale production of those investigational products. The primary activity at the site currently is bulk production, especially for Orencia (abatacept), BMS’ rheumatoid arthritis product.
“Biologics are increasingly important in the treatment of serious diseases and are a growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president, Global Manufacturing & Supply. “This initiative is designed to accelerate the development of new biologics medicines through the closer alignment of biologics research and development, and manufacturing.”
The Devens site is about 40 miles northeast of Boston; BMS says that the availability of educational resources, trained workers and the state’s Life Sciences initiative have been factors in the site selection.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
